Merck & CompanyvsZenas BioPharma

MRK and ZBIO stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

ZBIO

Zenas BioPharma, Inc.

$23.85

Value $1.6B

-4.75%
ZBIO's page

Merck & Company (MRK) has a market value of $331B and Zenas BioPharma (ZBIO) $1.6B. Over the last year, with dividends, MRK moved +44.8% and ZBIO -35.8%. Dividend yield: MRK 2.54%, ZBIO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    ZBIO$1.6B

    MRK is 204 times ZBIO

  • Revenue, 12 months

    MRK$67.4B

    ZBIO$11M

    MRK is 6,125 times ZBIO

  • Net income, 12 months

    MRK$2.5B

    ZBIO-$542M

  • Operating margin

    MRK–

    ZBIO-4,785.5%

  • ROIC

    MRK3.9%

    ZBIO-102.7%

    106.6 points apart

  • P/E

    MRK134.8

    ZBIO–

  • Dividend yield

    MRK2.5%

    ZBIO0.0%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+44.8%

ZBIO-35.8%

50100150DecFebAprJunAugOct
Returns by period
PeriodMRKWith dividendsZBIOWith dividends
1 year since November 19, 2025+44.8%Price +40.7%-35.8%Price -35.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyZBIOZenas BioPharma

Valuation

MRKZBIO
Valuation
Price$133.72$23.85
Market value$331B$1.6B
Enterprise value (EV)$375B$1.2B
P/E134.8–
P/E, 5-year median14.8–
P/B7.47.6
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKZBIO
Results and growth
Revenue, 12 months$67.4B$11M
Net income, 12 months$2.5B-$542M
Free cash flow, 12 months$14.7B-$243M
Earnings per share, 12 months$0.98-$10.05
Revenue growth, year on year1.3%100.0%
Revenue growth a year, past+9.4%over 5 years-55.3%over 2 years
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKZBIO
Margins and returns on capital
Gross margin71.8%–
Operating margin–-4,785.5%
Net margin3.6%-4,925.5%
ROIC3.9%-102.7%
ROE5.2%-219.6%

Balance sheet

MRKZBIO
Balance sheet
Cash$9.7B$647M
Total debt$53.8B$225M
Net debt / EBITDA5.7–
Interest cover2.4×-71.8×

Dividends and buybacks

MRKZBIO
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or ZBIO

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Zenas BioPharma?

By market value, Merck & Company ($331B) is about 204.4 times Zenas BioPharma ($1.6B), at today's prices.

How did MRK and ZBIO stock do over the last 1 years?

Since November 19, 2025, MRK's price moved +40.7% and ZBIO's -35.8%. With dividends: MRK +44.8% (+44.8% a year), ZBIO -35.8% (-35.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or ZBIO?

The dividend yield at today's price is 2.54% for Merck & Company and none for Zenas BioPharma. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or Zenas BioPharma?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -4,925.5% for Zenas BioPharma, and the operating margin – and -4,785.5%. Revenue was $67.4B and $11M.

Which is the better investment, Merck & Company or Zenas BioPharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.